Daiichi Sankyo (OTCMKTS:DSNKY) Stock Rating Lowered by Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Separately, Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Get Daiichi Sankyo alerts:

Check Out Our Latest Stock Analysis on DSNKY

Daiichi Sankyo Stock Performance

OTCMKTS DSNKY opened at $16.00 on Monday. The firm’s fifty day moving average price is $16.49 and its two-hundred day moving average price is $17.61. The stock has a market cap of $29.81 billion, a PE ratio of 18.60, a PEG ratio of 2.89 and a beta of -0.18. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts expect that Daiichi Sankyo will post 0.96 EPS for the current fiscal year.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Recommended Stories

• Five stocks we like better than Daiichi Sankyo
• The Real Reason Amazon Hit a $3 Trillion Valuation
• System Upgrade: First Internet Bancorp Options Surge
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.